Clinical Trial: Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Single Dose, Randomized, Double-Blind, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Fact

Brief Summary: The purpose of this study is to determine the relative bioavailability of ReFacto AF as compared to ReFacto, when each is administered as 2-minute bolus infusions.

Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Wyeth is now a wholly owned subsidiary of Pfizer

Dates:
Date Received: June 5, 2002
Date Started:
Date Completion:
Last Updated: April 18, 2008
Last Verified: April 2008